OPTIC randomized patients with CP-CML whose disease was resistant or intolerant to ≥2 BCR::ABL1 TKIs or with a T315I mutation to 1 of 3 starting doses of ponatinib, with protocol-driven dose reductions upon achievement of a prespecified response milestone (≤1% BCR::ABL1IS) [21]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.